Sign inJoin waitlistJoin the waitlist

Jacob Laubach

Chief, Division of Plasma Cell Neoplasias · Mass General Brigham

Credentials: · · · ·

History

Division of Plasma Cell Neoplasias · Mass General Brigham
Present
Multiple Myeloma Program · Mass General Brigham
Present
Mass General Brigham
Present

Hematology and Medical Oncology
Duke University School of Medicine
2002–2005
Internal Medicine
Duke University School of Medicine
1999–2002
Duke University School of Medicine
1995–1999

Research

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
New England Journal of Medicine · 2015 · 956 citations
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
New England Journal of Medicine · 2016 · 865 citations
Ibrutinib in previously treated Waldenström's macroglobulinemia
New England Journal of Medicine · 2015 · 796 citations

Paul Richardson
167 papers
Ken Anderson
90 papers
Nikhil Munshi
47 papers
Irene Ghobrial
45 papers
RS
Robert Schlossman
35 papers
NR
Noopur Raje
34 papers
Omar Nadeem
24 papers
Sagar Lonial
24 papers
AY
Andrew Yee
21 papers
Peter Voorhees
20 papers
Elizabeth O’Donnell
19 papers
AJ
Andrzej Jakubowiak
17 papers

Clinical trials

Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM
Principal investigator · Active not recruiting · Phase 2
Jacob Laubach, MD
2021–2029
An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma
Principal investigator · Withdrawn · Phase 2
Dana-Farber Cancer Institute
2018–2024
Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma
Principal investigator · Completed · Phase 2
Dana-Farber Cancer Institute
2015–2025
Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM
Principal investigator · Completed · Phase 2
Dana-Farber Cancer Institute
2015–2024